Head-to head comparison of mGlu1 and mGlu5 receptor activation in chronic treatment of absence epilepsy in WAG/Rij rats

D'Amore, V. and Santolini, I. and Celli, R. and Lionetto, L. and De Fusco, A. and Simmaco, M. and van Rijn, C. M. and Vieira, E. and Stauffer, S.R. and Conn, P. J. and Bosco, P. and Nicoletti, F. and van Luijtelaar, G. and Ngomba, R. T. (2014) Head-to head comparison of mGlu1 and mGlu5 receptor activation in chronic treatment of absence epilepsy in WAG/Rij rats. Neuropharmacology, 85 . pp. 91-103. ISSN 0028-3908

Documents
Head-to-Head.pdf

Request a copy
[img] PDF
Head-to-Head.pdf - Whole Document
Restricted to Repository staff only

2MB
Item Type:Article
Item Status:Live Archive

Abstract

Acute treatment with positive allosteric modulators (PAMs) of mGlu1 and mGlu5 metabotropic glutamate receptors (RO0711401 and VU0360172, respectively) reduces the incidence of spike-and wave discharges in the WAG/Rij rat model of absence epilepsy. However, from the therapeutic standpoint, it was important to establish whether tolerance developed to the action of these drugs. We administered either VU0360172 (3 mg/kg, s.c.) or RO0711401 (10 mg/kg, s.c.) to WAG/Rij rats twice daily for ten days. VU0360172 maintained its activity during the treatment, whereas rats developed tolerance to RO0711401 since the 3rd day of treatment and were still refractory to the drug two days after treatment withdrawal. In response to VU0360172, expression of mGlu5 receptors increased in the thalamus of WAG/Rij rats after 1 day of treatment, and remained elevated afterwards. VU0360172 also enhanced mGlu5 receptor expression in the cortex after 8 days of treatment without changing the expression of mGlu1a receptors. Treatment with RO0711401 enhanced the expression of both mGlu1a and mGlu5 receptors in the thalamus and cortex of WAG/Rij rats after 3–8 days of treatment. These data were different from those obtained in non-epileptic rats, in which repeated injections of RO0711401 and VU0360172 down-regulated the expression of mGlu1a and mGlu5 receptors. Levels of VU0360172 in the thalamus and cortex remained unaltered during the treatment, whereas levels of RO0711401 were reduced in the cortex at day 8 of treatment. These findings suggest that mGlu5 receptor PAMs are potential candidates for the treatment of absence epilepsy in humans

Keywords:Absence epilepsy, Spike-wave discharges, WAG/Rij rats, Tolerance, Chronic treatment, VU0360172, RO0711401, NotOAChecked
Subjects:B Subjects allied to Medicine > B210 Pharmacology
B Subjects allied to Medicine > B140 Neuroscience
Divisions:College of Science > School of Pharmacy
Related URLs:
ID Code:22178
Deposited On:03 Feb 2016 16:25

Repository Staff Only: item control page